Evommune vs Immuron
EVMN and IMRN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EVMN and IMRN compare
Immuron keeps more of each dollar of sales as profit, with a net margin of −47.7% compared with −947% at Evommune.
Evommune scores higher on the StockData Score (7 against 4 for Immuron), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EVMN | IMRN |
|---|---|---|
| Size and price | ||
| Market cap | $313M | – |
| Share price | $8.62 | $0.927 |
| Change, 1 year | −55.4% | −42.4% |
| Change, 5 years | – | −73.0% |
| Beta (5Y) | 0.92 | 0.38 |
| Employees | 48 | 7 |
| StockData Score | ||
| Total score | 7 (better) | 4 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 31.3× | – |
| P/B | 1.1× | – |
| FCF yield | −23.9% | – |
| Growth | ||
| Revenue growth (TTM) | – | 5.9% |
| Revenue growth, 5Y average | – | 121% |
| Profitability | ||
| Gross margin | – | 64.5% |
| Operating margin | −1019% | −49.9% (better) |
| Net margin | −947% | −47.7% (better) |
| FCF margin | −747% | −42.3% (better) |
| Return on equity | −142% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −261.7× |
| Current ratio | 11.68 (better) | 7.26 |
| Altman Z-score | 6.09 | – |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 95.4% | 0.02% |
| Held by insiders | 51.6% | 1.9% |
| Insider net buying, 12 months | −$2.1M | – |
| Short interest, % of float | 19.3% | – |
Go deeper
- EVMN stock overview
- EVMN income statement
- EVMN valuation and score
- IMRN stock overview
- IMRN income statement
- IMRN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.